9 million Medicare beneficiaries to benefit from new drug pricing, but careful monitoring needed

The US Department of Health and Human Services (HHS) announced last week that it has negotiated lower prices for 10 high-cost medications—set to take effect in 2026—for individuals with Medicare Part D coverage, which covers around 9 million older adults. The negotiated medications treat conditions such as heart disease, diabetes, and cancer.

Minal Patel, professor of Health Behavior & Health Equity at the University of Michigan School of Public Health, notes the negotiations as a significant step toward reducing healthcare costs.

"The successful negotiation of the list price for high-cost medicines used to treat and manage some of the most prevalent chronic conditions demonstrates that change is possible when it comes to addressing the epidemic of health-related financial toxicity impacting a wide range of Americans," Patel said.

"While this negotiation was specific to the Medicare Part D program for older adults, it’s important to remember that nearly half of Americans across all insurance types report difficulty with affording healthcare and compromise care-seeking and disease management because of affordability challenges. One-third are forced into medical debt," Patel added.

Patel emphasized that the Centers for Medicare & Medicaid Services (CMS) must carefully monitor the implementation to ensure that the cost savings benefit the intended recipients.

"CMS must ensure the anticipated cost-savings for beneficiaries remain intact through the current, intermediary channels that determine what beneficiaries ultimately pay out-of-pocket," she added.

“This initiative marks a crucial development in making healthcare more affordable for millions, with widespread implications for future healthcare policy.”